1 completed. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
Follow Semafore Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors SF1126 - Advanced or Metastatic Solid Tumors, Cancer | Phase 1 | Completed | Semafore Pharmaceuticals | 44 | 2007-04-01 | 2013-06-13 |
Neoplasms (1)
SF 1126 (1)
United States (1)